Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Clinical evidence

OPERA-02

22 evidence topics · 8 sources

Objective
Location and study date
Registry dates and planned enrollment
ItemValue
Study start (actual)“2025-11-03”
Primary completion (estimated)“2028-12”
Study completion (estimated)“2032-01”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using investigator-assessed progression-free survival as the primary endpoint
Primary, key secondary, and other secondary endpoints
Endpoint roleEndpoint
Primary endpoint“PFS, as assessed by local investigator”
Key secondary endpoint“OS”
Other secondary endpoint“PFS (per BIRC)”
Other secondary endpoint“ORR, CBR, and DOR (per local investigator and BIRC)”
Other secondary endpoint“PFS2”
Other secondary endpoint“Safety and tolerability”
Other secondary endpoint“PK”
Other secondary endpoint“Patient-reported outcomes”
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

No results from OPERA-02 have been reported; primary completion is estimated for December 2028, and top-line data are anticipated in 2028. The trial enrolls participants with no prior systemic therapy for advanced breast cancer and tests palazestrant in combination with ribociclib, so its population and regimen are outside this indication of previously treated disease and palazestrant monotherapy. The primary endpoint is investigator-assessed PFS, with PFS by blinded independent central review as a secondary endpoint. Participants previously treated with fulvestrant, elacestrant, or an investigational endocrine therapy in any setting are excluded.